METTL3 RNA modifying enzyme inhibitor

efficacy in AML PDX model (50 mg/kg IP)

from 250k compound HTS

Nature, Apr. 26, 2021

Storm Therapeutics / University of Cambridge

The Storm Therapeutics/Cambridge METTL3 RNA methyltransferase inhibitor, STM-2457, is a first-in-class catalytic inhibitor of the METTL3 RNA modifying enzyme. DNA-methyltransferase and other epigenetic targets such as HDACs have been explored…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.